Lipocine Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Salt Lake City UT United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2014
NCT02081300
First Marketed Drug
2020
testosterone (delatestryl)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chief Medical Director, Lipocine, Inc. | Lipocine Inc. | LIPOCINE INC